LYCOS RETRIEVER 
Schering Plough
built 650 days ago
Schering Plough is a global pharmaceutical company committed to discovering and bringing to market new therapies and treatment programmes that can improve people’s health and save lives. The company’s core product lines are:
Source:
Schering Plough (SP), manufacturer of pegylated interferon alfa-2b (PegIntron) announced very preliminary information yesterday on results of the company's IDEAL trial, the first major trial that provides a head-to-head comparison of PegIntron versus Pegasys (pegylated interferon alfa-2a), manufactured by Roche. Combination treatment with PegIntron/ribavirin or Pegasys/ribavirin represents the current standard of care for chronic hepatitis C infection in the U.S. and in most developed countries.
Source:
In 2000, Schering Plough bought a new campus in Summit, New Jersey from Novartis. The company plans to make this location its second largest corporate complex in the world after its current $20 million renovation.
Source:
Schering-Plough Corporation is a major U.S.-based manufacturer of pharmaceuticals. The company's leading prescription drug is the allergy medication Claritin, with 2001 sales of $3.2 billion. Other allergy and respiratory treatments include Clarinex, the firm's next-generation allergy treatment, and Nasonex, a nasal spray for allergies with 2001 sales of $524 million. In the area of anti-infective and anticancer products, Schering-Plough makes Intron A, a treatment for hepatitis C with 2001 sales of $1.4 billion; PEG-Intron, a longer-acting form of Intron A; Temodar, used to treat malignant brain cancer; and Remicade, a treatment for Crohn's disease. Schering-Plough ... makes drugs to treat cardiovascular, dermatological, and central nervous system disorders. Overall, pharmaceuticals account for about 85 percent of company sales.
Source:
KENILWORTH, N.J., Jan 03, 2008 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corporation (SGP) today announced that its Board had elected Dr. Craig B. Thompson as a member of its Board of Directors, effective Jan. 2, 2008. Dr. Thompson is Director of the Abramson Cancer Center and Professor of Medicine at the University of Pennsylvania School of Medicine in Philadelphia.
Source:
Under terms of the agreement, Schering-Plough will grant to Three Rivers a non-exclusive, non-sublicensable license to its U.S. ribavirin patents. Three Rivers will pay to Schering-Plough a royalty on its ribavirin sales. The agreement does not affect Three Rivers' reported patent litigation with Ribapharm, Inc.
Source:
MORE ABOUT
Schering Plough